{"title":"Trends and perspectives in the HIV vaccine research over the past thirty-five years: A scientometrics analysis through CiteSpace.","authors":"Xuannan Chen, Yizhou Zhuo, Yu Lai","doi":"10.24875/AIDSRev.25000018","DOIUrl":null,"url":null,"abstract":"<p><p>Despite advances in antiretroviral therapy, developing an effective human immunodeficiency virus (HIV) vaccine remains pivotal for epidemic control. Through a scientometric analysis of 19,863 publications from the Web of Science Core Collection (1989-2023) using CiteSpace, this study delineates evolving trends and emerging frontiers in HIV vaccine research. The United States dominated contributions, with institutions like the National Institutes of Health and Harvard leading productivity. Clustering revealed two interconnected research trajectories, which are broad neutralizing antibody development, broad neutralizing antibody precursors, and immune mechanism exploration. Despite efficacy trials not resulting in licensed HIV vaccine advancements in antigen design and adjuvant strategies, they show promise. Key findings indicated structural biology, germinal center (GC) dynamics, antibody-dependent cellular cytotoxicity, and glycosylation shielding as pivotal research domains. Critical barriers include generating a specific immune response to new epitopes and glycosylation-mediated immune evasion. Future efforts should prioritize GC optimization to enhance B-cell affinity maturation, structure-guided epitope targeting through cryo-electron microscopy, and advances in antigen delivery. In addition, engineering vaccines to expand CXCR5+ T follicular helper cell populations may improve durable humoral immunity. This analysis underscores the necessity of multidisciplinary approaches to overcome HIV vaccine hurdles.</p>","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":" ","pages":"138-152"},"PeriodicalIF":2.0000,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.24875/AIDSRev.25000018","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Despite advances in antiretroviral therapy, developing an effective human immunodeficiency virus (HIV) vaccine remains pivotal for epidemic control. Through a scientometric analysis of 19,863 publications from the Web of Science Core Collection (1989-2023) using CiteSpace, this study delineates evolving trends and emerging frontiers in HIV vaccine research. The United States dominated contributions, with institutions like the National Institutes of Health and Harvard leading productivity. Clustering revealed two interconnected research trajectories, which are broad neutralizing antibody development, broad neutralizing antibody precursors, and immune mechanism exploration. Despite efficacy trials not resulting in licensed HIV vaccine advancements in antigen design and adjuvant strategies, they show promise. Key findings indicated structural biology, germinal center (GC) dynamics, antibody-dependent cellular cytotoxicity, and glycosylation shielding as pivotal research domains. Critical barriers include generating a specific immune response to new epitopes and glycosylation-mediated immune evasion. Future efforts should prioritize GC optimization to enhance B-cell affinity maturation, structure-guided epitope targeting through cryo-electron microscopy, and advances in antigen delivery. In addition, engineering vaccines to expand CXCR5+ T follicular helper cell populations may improve durable humoral immunity. This analysis underscores the necessity of multidisciplinary approaches to overcome HIV vaccine hurdles.
尽管抗逆转录病毒疗法取得了进展,但开发有效的人类免疫缺陷病毒(HIV)疫苗仍然是控制流行病的关键。通过使用CiteSpace对Web of Science核心馆藏(1989-2023)的19,863篇出版物进行科学计量学分析,本研究描绘了艾滋病毒疫苗研究的发展趋势和新兴前沿。美国的贡献占主导地位,美国国立卫生研究院(National Institutes of Health)和哈佛大学(Harvard)等机构的生产力处于领先地位。聚类揭示了广泛中和抗体开发、广泛中和抗体前体和免疫机制探索两条相互关联的研究轨迹。尽管有效性试验没有导致许可的HIV疫苗在抗原设计和佐剂策略方面取得进展,但它们显示出了希望。主要发现表明结构生物学、生发中心动力学、抗体依赖性细胞毒性和糖基化屏蔽是关键的研究领域。关键的障碍包括对新的表位产生特异性免疫反应和糖基化介导的免疫逃避。未来的工作应优先考虑GC优化以增强b细胞亲和成熟,通过冷冻电子显微镜进行结构引导的表位靶向,以及抗原递送的进展。此外,扩大CXCR5+ T滤泡辅助细胞群的工程疫苗可能改善持久的体液免疫。这一分析强调了采用多学科方法克服艾滋病毒疫苗障碍的必要性。
期刊介绍:
AIDS Reviews publishes papers reporting original scientific, clinical, epidemiologic and social research which contribute to the overall knowledge of the field of the acquired immunodeficiency syndrome and human retrovirology. Currently, the Journal publishes review articles (usually by invitation, but spontaneous submitted articles will also be considered). Manuscripts submitted to AIDS Reviews will be accepted on the understanding that the authors have not submitted the paper to another journal or published the material elsewhere.